Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model

Investigative Radiology

Volumn 41, Issue 9, 2006, Pages 691-696

  Tang, Jin Shan ^a   Choy, Garry ^a   Bernardo, Marcelino ^a   Thomasson, David ^a   Libutti, Steven K ^a   Choyke, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenic inhibitor; Antivascular therapy TNF ; Coefficients of variation; DCE MRI; General kinetic model; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; GADOLINIUM PENTETATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COLON CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EARLY DIAGNOSIS; HISTOPATHOLOGY; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; VASCULAR TUMOR;

EID: 33747060166     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000233882.83800.fb     Document Type: Article

References (12)

1. Neeman M. Functional and molecular MR imaging of angiogenesis: seeing the target, seeing it work. J Cell Biochem Suppl. 2002;39:11-17.
2. Roberts TP, Turetschek K, Preda A, et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol. 2002;9(suppl 2):S511-S513.
3. Miller JC, Pien HH, Sahani D, et al. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005;97:172-187.
4. Marzola P, Ramponi S, Nicolato E, et al. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents. Invest Radiol. 2005;40:421-429.
5. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol. 2003;76:S60-S80.
6. Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol. 2003;76:S87-S91.
7. Kiessling F, Heilmann M, Vosseler S, et al. Dynamic T1-weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging. Int J Cancer. 2003;104:113-120.
8. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2003;17:509-520.
9. Kothari M, Guermazi A, White D, et al. Imaging in antiangiogenesis trial: a clinical trials radiology perspective. Br J Radiol. 2003;76:S92-S96.
10. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging. 2002;16:407-422.
11. Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging. 2004;20:138-144.
12. Preda A, van Vliet M, Krestin GP, et al. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest Radiol. 2006;41:325-331.